Leading Global Pharmaceutical Company, Teva Pharmaceutical Industries, Transfers Stock Listing to the New York Stock Exchange from NASDAQ

Teva Pharmaceutical Industries, a leading global pharmaceutical company and world’s largest generic drug maker, began trading on the New York Stock Exchange (NYSE) today under the ticker symbol "TEVA” after the transfer of its stock listing to the NYSE from NASDAQ. Dr. Phillip Frost, Chairman of the Board of Directors and President and CEO Dr. Jeremy M. Levin were joined by Teva’s CFO, Eyal Desheh; President and CEO of Teva Americas, William S. Marth and employees from Teva’s businesses around the world to celebrate the company’s first day of trading on the NYSE by ringing The Opening Bell^SM.

Dr. Phillip Frost, Chairman of the Board of Directors and President and CEO Dr. Jeremy M. Levin, along with members of Teva Pharmaceutical's management team and employees from around the globe, ring the NYSE Opening Bell to commemorate Teva's transfer of its stock listing to the NYSE from NASDAQ. (Photo: Business Wire)

"Teva is a global pharmaceutical company and a leader in their industry with a dedication to their patients,” said Diederik Zandstra, Head of International Listings, NYSE Euronext. "We are proud that Teva has chosen to transfer to the NYSE and recognizes the value of our global community, market structure and technology. We look forward to our partnership with Teva and its shareholders.”

"We are pleased to partner with the NYSE and begin using their state of the art trading platform and market research,” stated Dr. Phillip Frost, Chairman of the Board of Directors of Teva. "We are joining a network of true innovators and leaders listed on the NYSE.”

Teva Pharmaceutical is the second largest company to transfer its stock listing to the NYSE from NASDAQ. Teva is the seventh company to transfer from NASDAQ to the NYSE in 2012 following Hercules Technology Growth Capital Inc. (NYSE: HTGC – 4/30/12); TD Ameritrade Holding Company (NYSE: AMTD – 4/25/12); Arabian American Development Co. (NYSE: ARSD – 4/2); Halcon Resources Corp (NYSE: HK – 3/26); Kaman Corporation (NYSE: KAMN – 2/7) and Team Inc. (NYSE: TISI – 1/3).

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,300 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 46,000 people around the world and reached $18.3 billion in net revenues in 2011. (Source: Teva Pharmaceutical Industries Ltd.)

About NYSE Euronext

NYSE Euronext (NYX) is a leading global operator of financial markets and provider of innovative trading technologies. The company's exchanges in Europe and the United States trade equities, futures, options, fixed-income and exchange-traded products. With approximately 8,000 listed issues (excluding European Structured Products), NYSE Euronext's equities markets — the New York Stock Exchange, NYSE Euronext, NYSE MKT, NYSE Alternext and NYSE Arca — represent one-third of the world’s equities trading, the most liquidity of any global exchange group. NYSE Euronext also operates NYSE Liffe, one of the leading European derivatives businesses and the world's second-largest derivatives business by value of trading. The company offers comprehensive commercial technology, connectivity and market data products and services through NYSE Technologies. NYSE Euronext is in the S&P 500 index. For more information, please visit: http://www.nyx.com.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50294199&lang=en